Pfizer
Where is Pfizer's Headquarters? Main Office Location
Quick Facts
Pfizer's Global Headquarters
Pfizer's main headquarters is located at 235 East 42nd Street, New York, NY 10017. The office serves as the central hub for the company's global operations in the Biotech sector.
Headquarters Overview
Founded in 1849, Pfizer has established its presence in New York, NY, positioning itself strategically within the Biotech industry.
Key Details
- Location: New York, NY
- Address: 235 East 42nd Street, New York, NY 10017
- Founded: 1849
- Employees: 83,000+
- Industry: Biotech
Office Environment
The headquarters features modern office facilities designed to support innovation and collaboration in the Biotech space.
Workplace Features
- State-of-the-art technology infrastructure
- Collaborative workspaces
- Modern amenities and facilities
- Strategic location for talent acquisition
Business Operations
Pfizer operates at the forefront of the Biotech industry, with its headquarters serving as the command center for strategic initiatives and product development.
Strategic Importance
- Innovation Hub: Central location for R&D and development
- Talent Hub: Access to skilled professionals in New York
- Market Position: Strategic presence in key Biotech market
- Growth Trajectory: Positioned for continued expansion
Industry Impact
As a player in the Biotech sector, Pfizer contributes to the technological advancement and innovation in its field.
Market Presence
- Serving customers in the Biotech space
- Continuous innovation and product development
- Strategic partnerships and collaborations
- Focus on scalable solutions
Future Outlook
Pfizer continues to invest in its headquarters and operations, positioning itself for growth in the evolving Biotech landscape.
About the Author
Related Company Reports
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza